08 Oct '16, 2pm

1st Patient Enrolled in Phase 2 Clinical Trial of SY-1425 Genomically Defined Patients w #AML or #MDS

1st Patient Enrolled in Phase 2 Clinical Trial of SY-1425 Genomically Defined Patients w #AML or #MDS

Under the aegis of the MDS Foundation, the International Working Group for Prognosis in MDS (IWG-PM) analyzed clinical features and outcome data from over 7000 patients and generated a method analyzing MDS patient prognosis more precisely than the initial IPSS. Novel components of this prognostic system include: five rather than three cytogenetic prognostic subgroups with specific and new classifications of a number of less common cytogenetic subsets, splitting the low marrow blast percentage value, and depth of cytopenias. In addition to the major prognostic variables of marrow blasts, cytogenetics and peripheral cytopenias, additive features for survival include patient age, performance status, serum ferritin and LDH. The IPSS-R calculator tool is accessible through the following URLs : http://www.mds-foundation.org/ipss-r-calculator/index.php or http://www.ipss-r.com . ...

Full article: http://www.mds-foundation.org/recent-news/

Tweets

Do your friends know what MDS is? If not, share...

aamds.org 08 Oct '16, 3pm

MDS happens because the bone marrow cells do not develop into mature blood cells. Instead, these blood cells stay within t...

This time next #weekend we'll be in #Colorado +...

mds-foundation.org 29 Sep '16, 8pm

MDS Patients & Caregivers LIVING with MDS . Whether you are a newly diagnosed patient, a long-term survivor, or caregiver,...